Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2019
Evaluate Ltd. releases annual “EvaluateMedtech World Preview 2018, Outlook to 2024” in conjunction with The Medtech Conference
Vantage releases its half-year analysis of sector performance: Pharma, Biotech and Medtech Half-Year Review 2018
Latest growth forecasts show optimism surrounding new therapies coming to market counterbalanced by more stringent pricing policy enforcement.
New Case Studies Highlight Niche Patient Population Identification and Analysis for Enhanced Portfolio Decision-making Using Evaluate’s Epi Analyzer
Fall comes as average cost of developing new drugs totals $4bn over the last 10 years.
Annual Pharma & Biotech World Preview Report to Launch at Bio 2017
New EP Vantage report sees the number of immuno-oncology combination trials triple and Keytruda steal the crown from Opdivo.
Annual "EvaluatePharma Orphan Drug 2017 Report" sees continued growth (CAGR 2017 to 2022: +11.1%) for orphan drugs, approximately double overall prescription…
EP Vantage Releases its Annual Analysis of Pharma and Medtech Sector Performance: 2016 Pharma and Medtech in Review Reports.
A perspective on the portfolio strategy of the top 20 pharma companies.
Annual "EP Vantage 2017 Preview" report discusses what’s in store for biopharma in the coming year.
Evaluate Ltd, the life science commercial intelligence firm, today announced that it has received significant investment from HgCapital’s Mercury Fund to support the…